Abstract
Abstract Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19–associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.
Keywords
MeSH Terms
Affiliated Institutions
Related Publications
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Abstract Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular ...
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
Purpose Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. Method...
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
Abstract Background As the number of patients increases, there is a growing understanding of the form of pneumonia sustained by the 2019 novel coronavirus (SARS-CoV-2), which ha...
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19. We studied consecutive symptomatic patients with l...
Hematological findings and complications of <scp>COVID</scp>‐19
Abstract COVID‐19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, w...
Publication Info
- Year
- 2020
- Type
- article
- Volume
- 135
- Issue
- 23
- Pages
- 2033-2040
- Citations
- 2420
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1182/blood.2020006000
- PMID
- 32339221
- PMCID
- PMC7273827